15 results about "Intercellular adhesion molecule" patented technology

The application relates to the technical field of medicines, and discloses application of gymnemon and a medicine thereof.According to the application, the gymnemon can be used for preparing medicines related to cardiovascular diseases, including medicines for improving heart failure, inhibiting myocardial hypertrophy, improving vascular endothelial function and reducing blood pressure, and further used for preparing medicines for reducing expressions of vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 and / or increasing serum NO level; the gymnemon can also be used for preparing medicines for regulating abnormal lipid metabolism, including medicines for reducing triglyceride and total cholesterol level; the gymnemon can also be used for preparing medicines for relieving liver injury, including medicines for reducing glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase level; and the gymnemon can also be used for preparing medicines for improving systemic inflammation and / or platelet and thrombin dysfunction.

The present invention relates to the field of brain injuries. More specifically, the present invention provides methods and compositions useful in the diagnosis / prognosis / assessment of brain injuries. In a specific embodiment, a method for identifying which patients with traumatic brain injury (TBI) require ahead computerized tomography (CT) scan for diagnosing acute intracranial pathology comprises the steps of (a) obtaining or collecting a sample from the patient; (b) measuring the levels of one or more biomarkers in the blood sample obtained from the patient, wherein the biomarkers comprise glial fibrillary acidic protein (GFAP), S100B, metallothionein 3 (MT3), neuron specific enolase (NSE) and intracellular adhesion molecule 5 (ICAM5); and (c) identifying the patient as requiring or not requiring a head CT scan based on the measured levels of one or more of biomarkers comprising GFAP, S100B, MT3, NSE and ICAM5.

The present application relates to an Intercellular Adhesion Molecule 2 (ICAM-2) binding polypeptide. This ICAM-2 binding polypeptide comprises a fibronectin type III (FN3) domain having at least one modified loop amino acid sequence and, optionally, a modified beta strand. The one or more modified loop sequences, together with the optional beta strand modifications, enable selective binding to ICAM-2. Also disclosed are conjugates that include the ICAM-2 binding polypeptide, polynucleotides encoding the same, and methods of using these materials for inhibiting transplant organ rejection as well as treatment of hypertension and cancer.

The present invention belongs to the technical field of antibodies, and particularly relates to anti-human intercellular adhesion molecule-1 antibodies, antibody pairs and their applications. The antibody is a first antibody or a second antibody. The amino acid sequences of CDR1-3 in the light chain variable region of the first antibody are shown in SEQ ID NOs. 3-5 respectively, and the amino acid sequences of CDR1-3 in the heavy chain variable region are shown in SEQ ID NOs. 8-10 respectively; the amino acid sequences of CDR1-3 in the light chain variable region of the second antibody are shown in SEQ ID NOs. 13-15 respectively, and the amino acid sequences of CDR1-3 in the heavy chain variable region are shown in SEQ ID NOs. 18-20 respectively. The present invention provides an antibody and an antibody pair that can specifically recognize human ICAM-1, and are used to develop an immunoassay system for detecting human ICAM-1, which has the advantages of high affinity and specificity, strong anti-interference ability, high detection sensitivity and good stability.

Antigen-binding molecules engineered to replace the light chain constant domain (CL) and heavy chain constant domain 1 (CH1) with HLA class I histocompatibility antigen alpha chain-E alpha-3 (HLA-E) / beta2 microglobulin (B2M) or intercellular adhesion molecule 1 domain 1 (ICAM-1 D1) / ICAM-1 D1 dimerization domain are described.

The present invention relates to the field of brain injuries. More specifically, the present invention provides methods and compositions useful in the diagnosis / prognosis / assessment of brain injuries. In a specific embodiment, a method for identifying which patients with traumatic brain injury (TBI) require a head computerized tomography (CT) scan for diagnosing acute intracranial pathology comprises the steps of (a) obtaining or collecting a sample from the patient; (b) measuring the levels of one or more biomarkers in the blood sample obtained from the patient, wherein the biomarkers comprise glial fibrillary acidic protein (GFAP), S100B, metallothionein 3 (MT3), neuron specific enolase (NSE) and intracellular adhesion molecule 5 (ICAM5); and (c) identifying the patient as requiring or not requiring a head CT scan based on the measured levels of one or more of biomarkers comprising GFAP, S100B, MT3, NSE and ICAM5.

An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).

The present invention relates to a specific antisense oligonucleotide which inhibits the expression of the adhesion molecule ICAM-1 in human cells. The present invention further relates to a vector containing said oligonucleotide and a host cell containing said vector or oligonucleotide and a pharmaceutical composition containing said oligonucleotide as well as uses thereof, in particular in the treatment of an inflammatory disease or condition in humans.

Antigen binding molecules are described that are engineered to replace the light chain constant domain (CL) and the heavy chain constant domain 1 (CH1) with an HLA class I histocompatible antigen alpha-E alpha-3 (HLA-E) / beta-2 microglobulin (B2M) or intercellular adhesion molecule 1 domain 1 (ICAM-1D1) / ICAM-1D1 dimerization domain.

A method for preparing an immune cell differentiated from a stem cell is provided. The method includes: (a) forming a coating containing a matrix on a surface; and (b) culturing a stem cell on the coating in the presence of a first cytokine combination to differentiate the stem cell into an immune cell, wherein the immune cell includes a γδ T cell (gamma delta T cell, GDT cell). The matrix includes: vascular cell adhesion molecule (VCAM); intercellular adhesion molecule (ICAM); and delta-like ligand 4 (DLL4). The first cytokine combination includes: stem cell factor (SCF); thrombopoietin (TPO); Fms-like tyrosine kinase 3 ligand (Flt3L); and interleukin-7 (IL-7). Moreover, a source of the stem cell includes umbilical cord blood or an induced pluripotent stem cell (iPSC), and the stem cell is CD34 positive.

Methods of diagnosing and monitoring liver diseases are disclosed. The method includes measuring in a blood sample of the subject an amount of Von Willebrand factor (VWF) and at least one protein biomarker selected from the group consisting of sulfhydryl oxidase 1 (QSOX1), complement component C7 (C7), intercellular adhesion molecule- 1 (ICAM) and platelet glycoprotein V (GP5). Kits for diagnosing and monitoring are also disclosed.

An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).

The invention discloses a human umbilical cord mesenchymal stem cell three-dimensional aggregate as well as a preparation method and application thereof. The human umbilical cord mesenchymal stem cell aggregate is obtained by adding fusion proteins hE-cadhein-Fc and hN-cadhein-Fc into human umbilical cord mesenchymal stem cells and co-culturing the fusion proteins hE-cadhein-Fc and hN-cadhein-Fc into the human umbilical cord mesenchymal stem cells, the hE-cadherin-Fc is a fusion protein composed of a human intercellular adhesion molecule E-cadherin and an Fc domain of immunoglobulin G, and the hN-cadherin-Fc is a fusion protein composed of an extracellular structural domain of a human intercellular adhesion molecule N-cadherin and an Fc domain of immunoglobulin G. The three-dimensional culture technology of the mesenchymal stem cells can better simulate the in-vivo growth microenvironment of the cells. The invention provides a preparation method for promoting the formation of the three-dimensional culture mesenchymal stem cell aggregate and exerting better biology through cadherin matrix energization. According to the method, the biological characteristics of the mesenchymal stem cells can be optimized, and a remarkable treatment effect is achieved in the aspect of treatment of diabetic nephropathy.

This invention pertains to methods of treating cancer and lymphocyte mediated diseases using Intercellular Adhesion Molecule (ICAM)-modulating agents.

The invention provides application of a CFB (circulating fluid bed) inhibitor Iptacopan in atherosclerosis, the increase of Iptacopan is applicable to clinical atherosclerosis diseases, and in-vitro experiment results show that the CFB inhibitor Iptacopan can remarkably inhibit cell migration and proliferation of foaming human umbilical vein endothelial cells (HUVEC) and accumulation of reactive oxygen species (ROS) and reduce lipid deposition; according to the present invention, with the application of the target CFB, the plaque vulnerability process can be completely intervened, the angiogenesis induced by the oxidative low density lipoprotein (ox-LDL) can be blocked, the adhesion and the chemotaxis of the mononuclear cells can be inhibited by down-regulating the intercellular adhesion molecule-1 and the mononuclear cell chemotactic protein 1 (MCP1), the inflammatory factor expression of interleukin-1 beta (IL1beta) / interleukin-6 (IL6) can be reduced, and the results show that the target CFB can completely intervene the plaque vulnerability process, the inhibitor Iptacopan shows a huge treatment potential.